何凌云,张敏,官梅光,陈伟,吴维玲,阮景明

• 1:邵武市立医院心血管内科
• 2:邵武市立医院导管室
• 3:邵武市立医院放射影像科
• 4:邵武市立医院药剂科

摘要(Abstract)：

目的 探讨达格列净联合比索洛尔在急性ST段抬高型心肌梗死（ST-segment elevation myocardial infarction,STEMI）接受经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）患者中的应用效果。方法 选取92例STEMI患者作为研究对象，随机分为联合组（给予达格列净联合比索洛尔治疗，n=46）、单一组（给予比索洛尔治疗，n=46）。比较2组的疗效，心脏功能指标、定量血流分数（quantitative flow ratio,QFR）、心肌损伤及灌注指标、心血管风险指标及不良反应的发生情况。结果 治疗后，联合组的总有效率为89.13%，显著高于单一组的71.74%(P<0.05)。2组的QFR、左心室射血分数（left ventricular ejection fraction,LVEF）、心肌梗死溶栓（thrombolysis in myocardial infarction,TIMI）血流3级占比、ST段回落值（ST segment recovery value,STR）均显著升高，且联合组均显著高于单一组（P<0.05）;2组的左心室收缩末期内径（left ventricular end-systolic dimension,LVESD）、左心室舒张末期内径（left ventricular end-diastolic dimension,LVEDD）、肌红蛋白（Myoglobin）、肌酸激酶同工酶MB(creatine kinase-MB,CK-MB)、乳酸脱氢酶（lactate dehydrogenase,LDH）、心型脂肪酸结合蛋白（heart-type fatty acid binding protein,H-FABP）、血浆动脉粥样硬化指数（atherogenic index of plasma,AIP）、甘油三酯葡萄糖（triglyceride-glucose,TyG）指数、全血组织蛋白酶D(cathepsin D,CTSD)、缺血修饰白蛋白（ischemia modified albumin,IMA）水平均显著降低，且联合组均显著低于单一组（P<0.05）。2组不良反应发生率比较差异无统计学意义（P>0.05）。结论 达格列净联合比索洛尔治疗STEMI经PCI患者具有显著疗效，能促进心功能恢复，改善冠状动脉血流灌注，减轻心肌损伤，并降低心血管风险指标，且安全性良好。

关键词(KeyWords)： 达格列净;比索洛尔;急性ST段抬高型心肌梗死;经皮冠状动脉介入治疗;心功能

Abstract:

Keywords:

基金项目(Foundation): 南平市科技计划项目（编号：N2024LH035）

作者(Author): 何凌云,张敏,官梅光,陈伟,吴维玲,阮景明

参考文献(References)：

• [1]张涛，李爱敏，张金霞，等.急性ST段抬高型心肌梗死总缺血时间与急诊经皮冠状动脉介入治疗后1年内主要不良心血管事件发生风险的关系[J].中国循环杂志，2024,39(10):976-982.ZHANG Tao, LI Aimin, ZHANG Jinxia, et al.Association between total ischemic time and risk of major adverse cardiovascular events within 1 year after primary percutaneous coronary intervention in patients with ST segment elevation myocardial infarction[J]. Chinese Circulation Journal,2024,39(10):976-982.
• [2]贺文帅，王鹏飞，赵丽敏，等.替罗非班对急性ST段抬高型心肌梗死患者介入治疗后心功能及临床预后的影响[J].西北药学杂志，2025,40(1):153-158.HE Wenshuai,WANG Pengfei,ZHAO Limin, et al.Effect of tirofiban on cardiac function and clinical prognosis in patients with acute ST segment elevation myocardial infarction after interventional treatment[J].Northwest Pharmaceutical Journal,2025,40(1):153-158.
• [3]贾丽丽，王亚琦，张永忠.伊伐布雷定联合比索洛尔治疗老年缺血性心肌病心力衰竭的疗效[J].中国老年学杂志，2024,44(4):771-774.JIA Lili,WANG Yaqi,ZHANG Yongzhong. The efficacy of ivabradine combined with bisoprolol in the treatment of heart failure in elderly patients with ischemic cardiomyopathy[J]. Chinese Journal of Gerontology,2024,44(4):771-774.
• [4] MODZELEWSKI K L,PIPILAS A,BOSCH N A.Comparative outcomes of empagliflozin to dapagliflozin in patients with heart failure[J]. JAMA Netw Open,2024,7(5):e249305.
• [5]李枝怀，董玲，金鹏，等.恩格列净对老年急性心肌梗死患者PCI术后心功能不全的改善作用及安全性[J].中国老年学杂志，2024,44(22):5394-5397.LI Zhihuai,DONG Ling,JIN Peng, et al. The improvement effect and safety of empagliflozin on postoperative cardiac dysfunction in elderly patients with acute myocardial infarction after PCI[J]. Chinese Journal of Gerontology,2024,44(22):5394-5397.
• [6]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南（2019）[J].中华心血管病杂志，2019,47(10):766-783.Chinese Society of Cardiology,Editorial Committee of Chinese Journal of Cardiovascular Disease. 2019 Chinese Society of Cardiology(CSC)guidelines for the diagnosis and management of patients with ST segment elevation myocardial infarction[J]. Chinese Journal of Cardiology,2019,47(10):766-783.
• [7]曲曼青，张喜军，苏轶楣，等.匹伐他汀联合心肺康复训练对老年心肌梗死患者PCI术后疗效及血脂水平的影响[J].中国老年学杂志，2023,43(14):3338-3342.QU Manqing,ZHANG Xijun,SU Yimei, et al. The effect of pitavastatin combined with cardiopulmonary rehabilitation training on the postoperative efficacy and blood lipid levels of elderly patients with myocardial infarction after PCI[J].Chinese Journal of Gerontology,2023,43(14):3338-3342.
• [8] FEZZI S,DING D,SCARSINI R,et al. Integrated assessment of computational coronary physiology from a single angiographic view in patients undergoing TAVI[J].Circ Cardiovasc Interv,2023,16(10):e013185.
• [9]修天元，吕晓翠，张津宁，等.不同时间应用达格列净对急性心肌梗死经皮冠脉介入术患者冠状动脉微循环、心功能及生活质量的影响[J].西北药学杂志，2025,40(4):99-105.XIU Tianyuan,LV Xiaocui,ZHANG Jinning, et al.Effects of taking dapagliflozin at different times on coronary microcirculation,left ventricular function,and quality of life in percutaneous coronary intervention patients with acute myocardial infarction[J]. Northwest Pharmaceutical Journal,2025,40(4):99-105.
• [10] ESTEP J D,SALAH H M,KAPADIA S R, et al. HFSA scientific statement:Update on device based therapies in heart failure[J]. J Card Fail,2024,30(11):1472-1488.
• [11] STRAUSS M H,HALL A S,NARKIEWICZ K. The combination of Beta-Blockers and ACE inhibitors across the spectrum of cardiovascular diseases[J]. Cardiovasc Drugs Ther,2023,37(4):757-770.
• [12] MARTON A,SAFFARI S E,RAUH M, et al. Water conservation overrides osmotic diuresis during SGLT2inhibition in patients with heart failure[J]. J Am Coll Cardiol,2024,83(15):1386-1398.
• [13] LU Y,LI L,LI Q, et al. Effect of nebivolol on erectile function:A systematic review and Meta-analysis of randomized controlled trials[J]. J Sex Med,2025,22(2):307-316.
• [14] YALURI N,STAN?áKOVáYALURI A，?E?UCH P, et al. Cardiac biomarkers and their role in identifying increased risk of cardiovascular complications in COVID-19 patients[J]. Diagnostics(Basel),2023,13(15):2508.
• [15] YANG Z W,GONG H X,KAN F Q, et al. Association between the triglyceride glucose(TyG)index and the risk of acute kidney injury in critically ill patients with heart failure:Analysis of the MIMIC-Ⅳdatabase[J]. Cardiovasc Diabetol,2023,22(1):232.
• [16] Desroys du Roure P,David T,Mallavialle A, et al.Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy[J]. J Immunother Cancer,2025,13(1):e009548.
• [17] CHEN W,ZHANG Y,WANG Z X, et al. Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition[J].Front Pharmacol,2023,14:1078205.
• [18] IMRE E,GUNHAN H G,EREL P,et al. SGLT2inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes:A real-world retrospective observational study[J]. Minerva Endocrinol(Torino),2023,48(3):295-304.
• [19] DABOUR M S,GEORGE M Y,DANIEL M R, et al.The cardioprotective and anticancer effects of SGLT2inhibitors:JACC:CardioOncology state-of-the-art review[J].JACC CardioOncol,2024,6(2):159-182.